Short Interest in Surrozen, Inc. (NASDAQ:SRZN) Drops By 46.2%

Surrozen, Inc. (NASDAQ:SRZNGet Free Report) was the target of a large drop in short interest in January. As of January 31st, there was short interest totalling 5,600 shares, a drop of 46.2% from the January 15th total of 10,400 shares. Based on an average trading volume of 11,900 shares, the short-interest ratio is currently 0.5 days. Approximately 0.3% of the company’s stock are sold short.

Surrozen Stock Up 4.6 %

NASDAQ:SRZN traded up $0.40 during trading hours on Monday, hitting $9.15. 22,704 shares of the company traded hands, compared to its average volume of 13,704. The firm’s 50-day simple moving average is $8.70 and its 200-day simple moving average is $8.05. Surrozen has a one year low of $4.50 and a one year high of $20.70. The company has a market cap of $18.67 million, a PE ratio of -0.53 and a beta of 0.39.

Hedge Funds Weigh In On Surrozen

Hedge funds have recently modified their holdings of the company. Vanguard Group Inc. raised its stake in shares of Surrozen by 3.2% during the 3rd quarter. Vanguard Group Inc. now owns 487,278 shares of the company’s stock worth $984,000 after purchasing an additional 15,299 shares during the period. Renaissance Technologies LLC raised its holdings in shares of Surrozen by 284.6% in the 1st quarter. Renaissance Technologies LLC now owns 102,298 shares of the company’s stock worth $62,000 after purchasing an additional 75,700 shares during the period. Bank of Montreal Can bought a new stake in shares of Surrozen in the 1st quarter worth approximately $377,000. Millennium Management LLC bought a new stake in shares of Surrozen in the 4th quarter worth approximately $72,000. Finally, FMR LLC bought a new stake in shares of Surrozen in the 2nd quarter worth approximately $744,000. Institutional investors own 51.27% of the company’s stock.

About Surrozen

(Get Free Report)

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. The company is developing antibody-based therapeutics with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.

See Also

Receive News & Ratings for Surrozen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surrozen and related companies with MarketBeat.com's FREE daily email newsletter.